Wave To Work Alone on RNA Editor as AATD Picture Becomes Clearer

Why It Matters

A successful disease‑modifying therapy would be the first FDA‑approved cure for AATD, unlocking a multi‑billion‑dollar market and validating RNA‑editing as a commercial drug platform.

Key Takeaways

• Wave advances WVE-006 RNA editing after GSK exit
• Korro's KRRO-110 failure drops shares 80%
• Beam's BEAM-302 targets accelerated FDA approval
• Tessera partners Regeneron for TSRA-196 gene therapy
• AATD market projected $6.2B by 2032

Pulse Analysis

Alpha‑1 antitrypsin deficiency (AATD) remains one of the few rare lung‑liver disorders without an FDA‑approved disease‑modifying therapy. The condition stems from a duplicated SERPINA1 gene that produces a dysfunctional protein, leading to progressive lung tissue loss and liver injury. Current care relies on intravenous augmentation, a costly palliative approach that does not address the underlying genetic defect. Analysts value the AATD market at $2.6 billion today, with forecasts pushing total addressable revenue to $6.2 billion by 2032, underscoring the commercial incentive for a curative solution.

Wave Life Sciences is now the sole holder of the RNA‑editing candidate WVE‑006 after GSK relinquished its stake, and the company plans to seek accelerated regulatory feedback by mid‑2026. The asset aims to correct the SERPINA1 mutation at the RNA level, offering a “drug‑like” pharmacokinetic profile that investors favor over permanent genome edits. Competing approaches include Beam Therapeutics’ base‑editing program BEAM‑302, which has already demonstrated genetic correction in early trials and is pursuing an accelerated approval pathway, and Tessera Therapeutics’ one‑time gene‑editing therapy TSRA‑196, backed by a $275 million Regeneron partnership.

The divergent modalities—RNA editing, base editing and traditional gene therapy—create a multi‑track race that could accommodate several market entrants, according to analysts. RNA‑editing platforms like Wave’s promise reversible dosing and conventional drug manufacturing, potentially easing payer acceptance, while base‑editing candidates such as Beam’s may set efficacy benchmarks. Meanwhile, Tessera’s partnership with Regeneron signals confidence in large‑scale commercial rollout for one‑time gene corrections. For investors, the recent Korro setback highlights the high‑risk nature of early‑stage RNA therapeutics, but the expanding pipeline suggests a robust upside as the first FDA‑approved AATD cure approaches.